Renin-angiotensin system inhibition and risk of infection and mortality in COVID-19: a systematic review and meta-analysis.

Anoop N Koshy Alexandra C MurphyOmar FarouqueJay RamchandLouise M BurrellMatias B Yudi

Published in: Internal medicine journal (2020)

Use of ACEI or ARB was not associated with a heightened susceptibility for a positive diagnosis of COVID-19. Furthermore, they were not associated with increased illness severity or mortality due to COVID-19. Randomised controlled trials are needed to address definitively the potential benefits or harms of RAS inhibitors in patients with COVID-19.

Keyphrases

coronavirus disease
sars cov
cardiovascular events
respiratory syndrome coronavirus
risk assessment
climate change
human health
wild type